Zhu, Shaoming
Zhang, Tian
Zheng, Lei
Liu, Hongtao
Song, Wenru
Liu, Delong
Li, Zihai
Pan, Chong-xian http://orcid.org/0000-0002-8588-3994
Article History
Received: 29 July 2021
Accepted: 7 September 2021
First Online: 27 September 2021
Declarations
:
: Not applicable.
: Not applicable.
: TZ: Research funding (to Duke) from Pfizer, Janssen, Acerta, Abbvie, Novartis, Merrimack, OmniSeq, PGDx, Merck, Mirati, Astellas and Regeneron; consulting/speaking with Genomic Health and Sanofi Aventis; and consulting/advisory board with AstraZeneca, Bayer, Pfizer, Foundation Medicine, Janssen, Amgen, BMS, Calithera, Dendreon and MJH Associates; Stock ownership/employment (spouse) from Capio Biosciences, Archimmune Therapeutics and Nanorobotics. LZ: grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed and Halozyme; paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, Datarevive, QED, Xilio, Natera, Novagenesis, Snow Lake Captials and Mingruizhiyao; and shareholder at Alphamab and Mingruzhiyao. HL: research support from Karyopharm and Bristol Myers Squibb, served at advisory board meetings of Agios and a consultant for Beigene, NGM Biopharm. WS: an employee of Kira Pharmaceuticals. DL attended advisory board meetings of AstraZeneca, Beigene, Rigel; serves on the Speaker bureaus of AstraZeneca, Beigene, Incyte, Janssen, Pharmacyclics and Rigel; and has research fundings from Acerta, Celgene, Denovo and Pfizer. ZL: Scientific advisory board member for Heat Biologics, Alphamab (chair), Hengenix and Ioknisys. CXP is a co-founder and shareholder of LP Therapeutics.